

Background



В

Over the last 25 ears

```
N?&; *; (%E*&'++('&*(@%&*(5"15+-(*9?#'$*9($5'O(*E*&N?&;"O1(&%+*; (5'E*(*R7'O9*9(#%@@*O;?&'$*+-(K0DSF(TUVVL

/"15*&(O?&;"O1(: %&3+%'9;('O9(9*@'O9;<(B9"AA"#?+$(;#5*9?+*;('O9(&*;7%O;","+"$"*;(B+%: *&(;$'AA"O1(&'$"%; (A%&(7'$"*O$;(: "$5("O#&*';*9('#?"$->
```

Changes over the last 25 ears

```
)?,;$'O#*(G;*<($&*'$',+*(,*5'E"%&'+(7&%,+*@F('@*O',+*(
$%(*E"9*0#*B,';*9("0$*&E*0$"%O(K)QS/)QF(TUVWL>(P";*';*(
'77&%'#5F(O%OB,+'@"O1
D77%&$?O"$"*; (A%&(9"E*&; "%O(&*@'"O('(#%O#*&O(A%&(XN())G
B A&*H?*O$+-(5'O9+*(#%O$&%++*9(;?,;$'O#*;
KS *"; *O, *&1F(Y&%E*&F(.'@7, *++F(Z(4%&7%OF(TUV[L
B S%&*(O?&; *; (5 'E*(7&*; #&", "O1(7&"E"+*1*; (K \ 'O1(*$( '+>F(
TUV[L
N * * 9(A%&(: %&37+' # * (O?&; * (: *++O *;;(%A * &"O1;('O9('(+'&1 * B
;#'+*(;$?9-($%(*R'@"O*($5*;*(&*+'$"%O;5"7;F(;%@*(%O1%"O1
```


D

,

G a:(?79'\$*()G("0(0?&; *; ((((((((

Q"@;(V('09(]<

- C 8;\$"@'\$*()G('09()GP;(7&*E'+*0#*("0(XN;^
- C X*+'\$"%O;5"7;(,*\$:**O()G('O9(:%&3(A'#\$%&;
- C 8E'+?'\\$*(0?\&;*;_(30\%:+*91*(\%\< (())G('09(;-@7\%@;("0



M D

1

- C Q(#&%;;B;*#\$"%O'+(;\$?9-
- C Q(@"R*9B@%9*;(;?&E*-(K%O+"O*('O9(@'"+*9(7'7*&(H?*;\$"%OO'"&*;L

Da a

C M&%@(N%E*@, *&(TUTU(\$%(S'(TUTV

0X2('77&%E'+

C

M :

Balanced a ified am ling elec a e e e e n a i e f he US RN la i n (T ink ff & S , 1997). Di ided in 4 a a b RN la i n i e.

Nine a e elec ed am ng he 50 a e and DC ing imal all ca i n. (Le & Leme h)

Ac i el licen ed RN (incl ding APRN) hen elec ed ing and m am ling

Ta ge ed 3,973 RN (e cl de bad add e e / email).

D

```
: Mea _e
M
Substances d dd:
  Illicit drugs (d. .. a a a, c ca d, d a da d, a c d , d );
  Prescription-type (Rx-type) medications (d. . . .
  bd dadd, ad, -accaldd,
  Energy drinks OTC a (1. ., Rdd B , 5-H
  E ( );
  Caffeinated beverages (>4 c /da d / d );
  Nicotine d c (\overline{d}, \overline{d}) bacc, \overline{d}-c a \overline{d} \overline{d}, a c \overline{d});
  CBD
```

M : M
! "#\$%&'()*+\$)*,!+-*&..*\$"#\$%&'()\$*/)&\$"0)1
2 3&\$%*4)&0*"\$)
30)\$(056%57'8%46)*10"9*/5\$"\$)*,!:;<!:=*>?@A-B
 "\$)*C5%D7"%*&*60)\$(056%57'=*5'*90)&%)0*&/7"'%\$=*

more info

O

N=1215 responses (30.6%), 1170 used for analysis

```
O@J?PE) / &.)=*QRJSP*CD5%)
S@J>*4) &0$*7.1,!GT@RJ@L*0&'9)T>@8QS-
>RJN*40$)U6)05)'()*,!GT@SJ@L*0&'9)T@8AA-J
<&.E C70V)1*5'*D7$65%&.$
R?P*C70V5'9*5'*"0#&'*&0)&$
AOP*$%&EE*70*(D&09)*'"0$)$
W@P*C70V5'9*E"..8%5/)
```

P / D E RN

D

/D RN

TABLE 4		•
Proportion *** *** Sphratent's using or Drugs ************************************		A COLUMN
Answered yes to remain your experie need that		
following in the past year:"	n	%
a casedonut ha bark di carediease use		2001/12
fossigung bad or guilty about use?	า้าว	M 741
smaller nettente with the anner same		E1 1
use interfered with your work should himportantes activities a	To be	NE.
a_กะละเจ้าสมูร์ท่าร่างดีเรียน เอ็ก คารู้ รื่องกา		
feeling with ack win, can've prodistannes.	220	^_ <u>1</u> _0
being under the minder of at work?	.9	
blackouts or flashtuaic	22	9-7-2
heaning policy series from the (e.g., memory, series, ble earling)?	*	ILK "IMI
urself record, to uv. lweekly, aanvr friu (note l> substances?	20	24,5

, **,** , ,

T , A. M., Y , J. M., S , V. L., S , C. L., E , H. S., & B , H. (2021). R



P D M -R E N

		n.	Prescrinting Type Misses 3 0/, 10	UDP/826/UP
Per-caived vanilability	we lot	518	8,1	1 00
ter Miller - 1960 v. 1960 fülk auch schrieber Fachs (i.e. 1960 v.) vollen. Schrieber	Moderate	4550	0.00 Q	<u> </u>
Frequency of the International	Fign	220	14.1 0×1	1.07 (0.20%)
rrequences and ministration	Somainmes	66 ₁	7.1	11.1370.70-1.8
	Often	98		υ.61-2. Χ΄ (143) 15
Perceiva ed knowledge	*Le* W	18-10	^ <u>7</u> 340	100 Proper
	Mode ite.	680	6.7	2.74 (0.37-20.
	High	37		0.03 (0.01 13.00
Workplace controls.	Aguequate	1065	8.7	1.00
	TO Um	36	1.7	1 V \ V . 0 2 V . 1 V ;

D M

5. Discussion

!"##\$\&'()'*+, '-*". &')/0./01-

- C N?&; *(7&*; #&"7\$"%OB\$-7*(@";?; *(;\$"++(*R#**9;(\$5'\$(%A(\$5*(1*O*&'+(G>)>(7%7?+'\$"%O
- C N?&; *() G(P"; %&9 *&(&' \$*; (K`>` a L; "@"+'&(\$%(\$5* G)(7%7?+'\$"%0(Kb>] a L(K) QS /) QF(TUTUL
- C c %&37+'#*(*R7%; ?&*(K'E'"+', "+"\$-F(A&*H?*O\$(
 '9@"O"; \$&'\$"%OF(30%: +*91*F(: %&37+'#*(#%O\$&%+; L(
 :';(';; %#"'\$*9(: "\$5(7&*; #&"7\$"%O(9&?1(@";?;*

!"##\$\&'()'*+, '-*". &')/0./01-

- C N?&; *; (0%\$(@?#5(#%OA"9*O#*("O(\$5*"&(',"+"\$-(\$%("9*O\$"A-(#%++*'1?*;(:"\$5(7%;;",+*()GP
- C M'E%&',+*(%7"O"%O;(%A('(O?&;*_;(',"+"\$-(\$%(;?##**9("O(\$&*'\$@*O\$('O9 &*B*O\$*&(7&'#\$"#*
- C)?77%&\$"E*('\$\$"\$?9*;(\$%:'&9("@7'"&*9(O?&;*;>

Bac d Me d Re D c

R

Thank you very much!

Comments or Questions?